William Chou
Fortuna: 37 643 $ al 31/05/2026
Fortuna: 37 643 $ al 31/05/2026
Dr. William Chou is a President, Chief Executive Officer & Director at Passage Bio, Inc. He is on the Board of Directors at Passage Bio, Inc. Dr. Chou was previously employed as a Chief Executive Officer by Aruvant Sciences, Inc. and a Vice President by Novartis Pharma AG.
He received his undergraduate degree from Princeton University, an MBA from Yale School of Management and a doctorate degree from the University of Pittsburgh School of Medicine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PASSAGE BIO, INC. 0,2 % | 16/03/2026 | 6.524 ( 0,2 % ) | 37 643 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PASSAGE BIO, INC. | Director Ejecutivo | 10/10/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Director Ejecutivo | 01/10/2022 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Corporate Officer/Principal | 01/10/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Yale School of Management
Yale School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pittsburgh School of Medicine
University of Pittsburgh School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Passage Bio, Inc.
Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.